DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Clinical trials for DLBCL ARISING FROM FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL ARISING FROM FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL ARISING FROM FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy targets Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…
Matched conditions: DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo aims to boost CAR-T success in hard-to-treat lymphomas
Disease control TerminatedThis study tests whether adding an experimental drug called E7777 before standard CAR-T therapy can help people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 30 participants will receive E7777 followed by chemotherapy and a CAR-T produc…
Matched conditions: DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC